Patent · US Active

Subcutaneous administration of ADAMTS13

US11779635B2 · kind B2 · utility

0Cited by

0References

17Claims

0Family size

Assignee

Takeda Pharmaceutical Company Limited · JP

Inventors

Alexandra Nathalie Kopic · Wien, AT
Werner Hoellriegl · Old Southern Main Road, AT
Barbara Plaimauer · Wien, AT
Hanspeter Rottensteiner · Wien, AT
Eva-Maria Muchitsch · Wien, AT

Key dates

Filing date	Nov 12, 2021
Grant date	Oct 10, 2023
Priority date	—
Expiry date	Dec 15, 2041

Classification

Technology area (CPC Y)Emerging Cross-Sectional Technologies
CPC primaryY02A50/30
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

This invention relates to methods of subcutaneous administration of ADAMTS13 formulations to a treat a disease or condition associated with ADAMTS13 and VWF dysfunction. Furthermore, evidence of the unexpectedly high bioavailability of ADAMTS13 formulations administered subcutaneously is provided herein.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.